Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 13, 2026
Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.
Journal: American journal of hematology
Published: May 29, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.
Journal: Blood cancer discovery
Published: May 18, 2026
Hematopoietic Cell Transplant Access and Patient Diversity.
Journal: JAMA network open
Published: May 05, 2026
Outcomes of Tocilizumab for Cytokine Release Syndrome after Post-Transplant Cyclophosphamide.
Journal: Transplantation and cellular therapy
Published: April 22, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.
Journal: Research square
Published: February 23, 2026
Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS.
Journal: Cell reports. Medicine
Published: July 02, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 16, 2025
Last Updated: 09/26/2026